PCSK9 inhibition: The next statin?

Journal of the American College of Cardiology

Volumn 59, Issue 25, 2012, Pages 2354-2355

  Vogel, Robert A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

low density lipoprotein cholesterol; PCSK9; REGN727 SAR236553; statin

Indexed keywords

ANACETRAPIB; ATORVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SAR 236553; SERINE PROTEINASE; STEROID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

BRAIN HEMORRHAGE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; INJECTION SITE REACTION; LEUKOCYTOCLASTIC VASCULITIS; LIPID METABOLISM; LIVER CLEARANCE; MISSENSE MUTATION; NOTE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84862176457     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.03.011     Document Type: Editorial

References (14)

1. The AIM-HIGH Investigators AIM-HIGH: niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
2. A.M. Tonkin, L. Chen Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Circulation 122 2010 850 852
3. M. Abifadel, M. Varret, J.P. Rabès, D. Allard, K. Ouguerram, M. Devillers Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat Genet 34 2003 154 156 (Pubitemid 36666925)
4. K.N. Maxwell, R.E. Soccio, E.M. Duncan, E. Sehayek, J.L. Breslow Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice J Lipid Res 44 2003 2109 2119 (Pubitemid 37509626)
5. O.N. Akram, A. Bernier, F. Petrides, G. Wong, G. Lambert Beyond LDL cholesterol, a new role for PCSK9 Arterioscler Thromb Vasc Biol 30 2010 1279 1281
6. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
7. J.M. McKenney, M.J. Koren, D.J. Kereiakes, C. Hanotin, A.-C. Ferrand, E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kenexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
8. S.S. Martin, R.S. Blumenthal, M. Miller LDL cholesterol: the lower the better Med Clin North Am 96 2012 13 26
9. J.C. LaRosa How much statin is enough? J Am Coll Cardiol 58 2011 1672 1673
10. S.D. Wiviott, C.P. Cannon The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy Curr Opin Lipidol 17 2006 628 630
11. T.M. Burton, R. Winslow FDA Warns on Statin Drugs: Labels on Popular Cholesterol Medicines Must Cite Risk of Diabetes, Memory Loss http://online.wsj.com/article/SB10001424052970203833004577251392001194250.html Accessed February 29, 2012
12. C.P. Cannon, S. Shah, H.M. Dansky, M. Davidson, E.A. Brinton, A.M. Gotto Jr. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
13. J.K. Liao, U. Lauf Pleiotropic effects of statins Annu Rev Pharmacol Toxicol 45 2005 89 118 (Pubitemid 40261799)
14. J.L. Goldstein, M.S. Brown History of discovery of the LDL receptor Arterioscler Thromb Vasc Biol 29 2009 431 438